Business
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
- 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue - - 2022 Recurring Revenue from Royalties Projected to
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"- 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue -\n - 2022 Recurring Revenue from Royalties Projected to Grow by Approximately 50% over Record Royalties in 2021 to Approximately $300 Million -\n - 2022 GAAP Operating Income Guidance of $350 to $380 Million Representing 32-36% Growth over Expected 2021 GAAP Operating Income -\n - 2022 GAAP Diluted EPS Guidance of $1.90 to $2.05 and 2022 Non-GAAP Diluted EPS Guidance of $2.05 to $2.20 -\n\n\nSAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year.\n\"Halozyme had another strong year of financial performance in 2021 with record revenues and profitability driven by strong growth of our wave 2 partner products including the subcutaneous forms of DARZALEX® and Phesgo®,\" said Dr. Helen Torley, president and chief executive officer. \"Also in 2021, we made substantial progress expanding the future opportunity set for our ENHANZE® technology. We signed an exciting new collaboration agreement with ViiV Healthcare to advance the use of our technology in infectious disease and small molecule applications. In 2022, we project at least four new products utilizing ENHANZE® will enter Phase 1 development, resulting in at least twenty partner programs in our pipeline. We look forward to strong continued total and royalty revenue growth, advancement of at least five ENHANZE® partner programs into Phase 2 and 3 development, and potential new ENHANZE® collaborations and new target nominations. We are also making strategic investments to further drive revenue growth and extend revenue durability. These include investments to expand robust API supply of high yield ENHANZE® and development of a new rHuPH20, with extended room temperature stability, and with patent protection to 2032 in Europe and 2034 in the US.\" \nAnticipated 2022 Key Events:\nProjected growth of approximately 50% in the Company's high-margin, recurring revenue stream from royalties to approximately $300 million driven by continued uptake of wave 2 launch products, subcutaneous DARZALEX® (daratumumab) and Phesgo® (pertuzumab, trastuzumab and hyaluronidase) utilizing ENHANZE® technology; At least five new Phase 2/3 starts for existing ENHANZE® programs; At least...